MUMBAI, India, April 20 -- Intellectual Property India has published a patent application (202617004754 A) filed by Adienne Pharma & Biotech SA, Lugano, Switzerland, on Jan. 17, for 'treatment of primary ctla-4 checkpoint related immunodeficiencies with 1h-indole-3-carboxaldehyde or 1-methylindole-3-carboxylic acid.'
Inventor(s) include Di Naro, Antonio Francesco; Giovagnoli, Stefano; Puccetti, Matteo; and Pariano, Marilena.
The application for the patent was published on April 17, under issue no. 16/2026.
According to the abstract released by the Intellectual Property India: "The present disclosure is directed to a method of treating a CTLA-4 checkpoint related immunodeficiency by administering a therapeutically effective amount of a ph...